LNR 653.1
Alternative Names: BIOP-653.1; LNR-653.1Latest Information Update: 28 Nov 2025
At a glance
- Originator Biophtha
- Developer Lanier Biotherapeutics
- Class Anti-inflammatories; Antipsoriatics; Bispecific antibodies; Eye disorder therapies
- Mechanism of Action IL17A protein inhibitors; Placenta growth factor inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic macular oedema; Psoriasis; Retinal vein occlusion; Wet age-related macular degeneration
Most Recent Events
- 28 Nov 2025 No recent reports of development identified for preclinical development in Diabetic-macular-oedema in USA (Parenteral)
- 28 Nov 2025 No recent reports of development identified for preclinical development in Psoriasis in USA (Parenteral)
- 28 Nov 2025 No recent reports of development identified for preclinical development in Retinal vein occlusion in USA (Parenteral)